Skip to main content
Top
Published in: Supportive Care in Cancer 3/2012

01-03-2012 | Original Article

The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA

Authors: Sherry L. Wolf, Debra L. Barton, Rui Qin, Edward J. Wos, Jeff A. Sloan, Heshan Liu, Neil K. Aaronson, Daniel V. Satele, Bassam I. Mattar, Nathan B. Green, Charles L. Loprinzi

Published in: Supportive Care in Cancer | Issue 3/2012

Login to get access

Abstract

Background

Chemotherapy-induced peripheral neuropathy (CIPN) is characterized by numbness, tingling, and shooting/burning pain. This analysis was performed to describe the relationship between numbness, tingling, and shooting/burning pain in patients with CIPN, as reported using the EORTC QLQ-CIPN20 (CIPN20).

Methods

Baseline CIPN20 data were provided for all patients on a prospective trial designed to treat patients with bothersome CIPN. Baseline frequencies for the items on the CIPN20 are primarily described by descriptive statistics and histograms, with correlational analyses between individual items.

Results

A majority of the 199 patients accrued to this study reported “quite a bit” to “very much” numbness (57%) or tingling (63%) in the hands compared to “a little” or “not at all” (numbness (43%), tingling (38%)). Fewer patients reported “quite a bit” to “very much” shooting/burning pain in the hands (18%). Numbness and tingling in the hands were highly correlated (r = 0.69), while neither were highly correlated with shooting/burning pain. Similar results were observed in the feet. More severe ratings for tingling and shooting/burning pain were ascribed to the lower extremities, as opposed to the upper extremities.

Conclusions

In patients with CIPN, severe sensory neuropathy symptoms (numbness, tingling) commonly exist without severe neuropathic pain symptoms (shooting/burning pain), while the reverse is not common. Symptoms in the feet should be evaluated distinctly from those in the hands as the experience of symptoms is not identical, for individual patients, in upper versus lower extremities.
Literature
1.
go back to reference Cavaletti G et al (1995) Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer 75(5):1141–1150PubMedCrossRef Cavaletti G et al (1995) Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer 75(5):1141–1150PubMedCrossRef
2.
go back to reference Cavaletti G et al (1998) Carboplatin toxic effects on the peripheral nervous system of the rat. Ann Oncol 9(4):443–447PubMedCrossRef Cavaletti G et al (1998) Carboplatin toxic effects on the peripheral nervous system of the rat. Ann Oncol 9(4):443–447PubMedCrossRef
3.
go back to reference Ocean AJ, Vahdat LT (2004) Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer 12(9):619–625PubMed Ocean AJ, Vahdat LT (2004) Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer 12(9):619–625PubMed
4.
go back to reference Pace A et al (1997) Paclitaxel neurotoxicity: clinical and neurophysiological study of 23 patients. Ital J Neurol Sci 18(2):73–79PubMedCrossRef Pace A et al (1997) Paclitaxel neurotoxicity: clinical and neurophysiological study of 23 patients. Ital J Neurol Sci 18(2):73–79PubMedCrossRef
5.
go back to reference Rowinsky EK et al (1993) Neurotoxicity of taxol. J Natl Cancer Inst Monogr 15:107–115PubMed Rowinsky EK et al (1993) Neurotoxicity of taxol. J Natl Cancer Inst Monogr 15:107–115PubMed
6.
go back to reference Verstappen CC et al (2003) Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63(15):1549–1563PubMedCrossRef Verstappen CC et al (2003) Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63(15):1549–1563PubMedCrossRef
8.
9.
go back to reference LoMonaco M et al (1992) Cisplatin neuropathy: clinical course and neurophysiological findings. J Neurol 239(4):199–204PubMedCrossRef LoMonaco M et al (1992) Cisplatin neuropathy: clinical course and neurophysiological findings. J Neurol 239(4):199–204PubMedCrossRef
10.
go back to reference Nikcevich DA et al (2008) A phase III randomized, placebo-controlled, double-blind study of intravenous calcium/magnesium to prevent oxaliplatin-induced sensory neurotoxicity, N04C7. J Clin Oncol 26(15):4009 Nikcevich DA et al (2008) A phase III randomized, placebo-controlled, double-blind study of intravenous calcium/magnesium to prevent oxaliplatin-induced sensory neurotoxicity, N04C7. J Clin Oncol 26(15):4009
11.
go back to reference Postma TJ et al (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41(8):1135–1139PubMedCrossRef Postma TJ et al (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41(8):1135–1139PubMedCrossRef
12.
go back to reference Binder A et al (2007) Pain in oxaliplatin-induced neuropathy—sensitisation in the peripheral and central nociceptive system. Eur J Cancer 43(18):2658–2663PubMedCrossRef Binder A et al (2007) Pain in oxaliplatin-induced neuropathy—sensitisation in the peripheral and central nociceptive system. Eur J Cancer 43(18):2658–2663PubMedCrossRef
13.
go back to reference Dougherty PM et al (2004) Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 109(1–2):132–142PubMedCrossRef Dougherty PM et al (2004) Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 109(1–2):132–142PubMedCrossRef
14.
go back to reference Cata JP et al (2006) Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol 72(3):151–169PubMed Cata JP et al (2006) Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol 72(3):151–169PubMed
15.
go back to reference Paice JA (2009) Clinical challenges: chemotherapy-induced peripheral neuropathy. Semin Oncol Nurs 25(2 Suppl 1):S8–S19PubMedCrossRef Paice JA (2009) Clinical challenges: chemotherapy-induced peripheral neuropathy. Semin Oncol Nurs 25(2 Suppl 1):S8–S19PubMedCrossRef
16.
go back to reference NCI Cancer Therapy Evaluation Program (2006) Common Terminology Criteria for Adverse Events version 3.0. National Cancer Institute, Bethesda NCI Cancer Therapy Evaluation Program (2006) Common Terminology Criteria for Adverse Events version 3.0. National Cancer Institute, Bethesda
17.
go back to reference Serlin RC et al (1995) When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61(2):277–284PubMedCrossRef Serlin RC et al (1995) When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61(2):277–284PubMedCrossRef
18.
go back to reference Barton D et al. (2011) A double blind, placebo controlled trial of a topical treatment for chemotherapy induced peripheral neuropathy: NCCTG trial N06CA. Supportive Care Cancer. 2010 May 25. [Epub ahead of print] Barton D et al. (2011) A double blind, placebo controlled trial of a topical treatment for chemotherapy induced peripheral neuropathy: NCCTG trial N06CA. Supportive Care Cancer. 2010 May 25. [Epub ahead of print]
19.
go back to reference Nunnally J, Bernstein I (1994) Psychometric theory, 3rd edn. McGraw-Hill, New York Nunnally J, Bernstein I (1994) Psychometric theory, 3rd edn. McGraw-Hill, New York
20.
go back to reference Liu H et al (2008) Comparing and validating simple measures of patient-reported peripheral neuropathy (PRPN) for NCCTG Clinical Trials: a pooled analysis of 2,440 patients (pts). J Clin Oncol 26:9534 Liu H et al (2008) Comparing and validating simple measures of patient-reported peripheral neuropathy (PRPN) for NCCTG Clinical Trials: a pooled analysis of 2,440 patients (pts). J Clin Oncol 26:9534
22.
Metadata
Title
The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA
Authors
Sherry L. Wolf
Debra L. Barton
Rui Qin
Edward J. Wos
Jeff A. Sloan
Heshan Liu
Neil K. Aaronson
Daniel V. Satele
Bassam I. Mattar
Nathan B. Green
Charles L. Loprinzi
Publication date
01-03-2012
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 3/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-011-1141-9

Other articles of this Issue 3/2012

Supportive Care in Cancer 3/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine